Table 1

Demographic characteristic of patients with and without stroke in Taiwan

VariablesStrokeP value
Yes
n=7550
No
n=30 200
Osteoporosis patients, n (%)1537 (20.36)5830 (19.30)<0.038
Period of developing osteoporosis median (IQR), years3.2 (1.4–6.1)6.5 (4.2–10.0)<0.001
Age mean (SD), years66.4 (9.3)66.3 (9.4)0.408
 Age group, n (%)
 50–592179 (28.86)8716 (28.86)
 60–692644 (35.02)10 576 (35.02)
 70–792148 (28.45)8592 (28.45)
>80579 (7.67)2316 (7.67)1.000
Sex, n (%)
 Males4624 (59.69)18 496 (59.69)
 Females3123 (40.31)12 492 (40.31)1.000
Comorbidity, n (%)
 Hypertension6498 (92.03)16 669 (55.20)<0.001
 Diabetes mellitus3888 (51.50)8355 (27.67)<0.001
 Hyperlipidaemia4926 (65.25)13 566 (44.92)<0.001
 Chronic kidney disease2094 (27.74)3884 (12.86)<0.001
 Chronic liver disease3221 (42.66)10 830 (35.86)<0.001
 Chronic pulmonary disease4797 (63.54)13 178 (43.64)<0.001
 Hyperthyroidism374 (4.95)1188 (3.93)<0.001
 Depression1612 (21.35)2784 (9.22)<0.001
Medication, n (%)
 Oral corticosteroids*1151 (15.25)2386 (7.90)<0.001
 Clopedigrel1624 (21.51)961 (3.18)<0.001
 Coumadin127 (1.68)80 (0.26)<0.001
 Aspirin3022 (40.03)3167 (10.49)<0.001
  • *Oral prednisolone equivalent to 5 mg/day.